I am very pleased to present the digital edition of November’s Pharmaceutical Market Europe.
Can pharma ‘take back control’ of the narrative?
Amid all the strong emotional reactions and reasoned arguments that Brexit evokes, the most common response today in the UK and Europe is simple: please let it be over soon.
Sadly it was all too predictable that the UK public would tire of the subject, confused by the huge technical complexity of leaving the EU and the choices it creates, and grow weary also of the division and vitriol it has unleashed in public life.
This Brexit fatigue is unfortunate, as there remain many questions to be answered. For pharma, as with so many other sectors, its greatest crime is in overwhelming all other economic, political and societal issues.
In this issue we highlight some of the latest Brexit developments, and our guest columnist Sarah Jones tackles the question of how pharma can try to ‘take back control’ of the UK life sciences narrative, after two and half years of it being subsumed by Brexit (see p15).
Whatever the Brexit outcome, the sector (which includes the UK’s world-class academic centres) needs to try its best to protect itself and promote its long-term interests, and those of the NHS and patients.
Andrew McConaghie
Group Editor, PME
Register here to receive email notification of future digital editions of PME or contact the subscriptions department to enquire about receiving a print copy of the magazine. More PMLiVE digital editions can be found here.
PME is also available to download as an app for iPhone and iPad
